Cks 17 | CAS# 99273-04-8 | HTLV I & II & HIV

Cks 17
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412992

CAS#: 99273-04-8

Description: Cks 17 is a 16-amino acid protein; has been synthesized; homologous to the first 16 amino acids of the P15E region of HTLV I & II & HIV.

Chemical Structure

Cks 17

CAS# 99273-04-8

Instruction

Theoretical Analysis

MedKoo Cat#: 412992
Name: Cks 17
CAS#: 99273-04-8
Chemical Formula: C87H148N26O24
Exact Mass: 1,941.12
Molecular Weight: 1,942.290
Elemental Analysis: C, 53.80; H, 7.68; N, 18.75; O, 19.77

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 322	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Cks 17; Cks17; Cks-17; Cks-17 peptide

IUPAC/Chemical Name: L-Leucine, L-leucyl-L-glutaminyl-L-asparaginyl-L-arginyl-L-arginylglycyl-L-leucyl-L-alpha-aspartyl-L-leucyl-L-leucyl-L-phenylalanyl-L-leucyl-L-lysyl-L-alpha-glutamylglycylglycyl-

InChi Key: RESSROXEVCGJLA-DFNTYYFDSA-N

InChi Code: InChI=1S/C87H148N26O24/c1-44(2)32-51(89)72(123)103-56(25-27-65(90)114)77(128)112-62(39-66(91)115)83(134)106-54(24-19-31-97-87(94)95)76(127)104-52(23-18-30-96-86(92)93)73(124)100-43-69(118)101-57(33-45(3)4)78(129)113-63(40-71(121)122)84(135)110-59(35-47(7)8)80(131)108-60(36-48(9)10)81(132)111-61(38-50-20-14-13-15-21-50)82(133)109-58(34-46(5)6)79(130)105-53(22-16-17-29-88)75(126)107-55(26-28-70(119)120)74(125)99-41-67(116)98-42-68(117)102-64(85(136)137)37-49(11)12/h13-15,20-21,44-49,51-64H,16-19,22-43,88-89H2,1-12H3,(H2,90,114)(H2,91,115)(H,98,116)(H,99,125)(H,100,124)(H,101,118)(H,102,117)(H,103,123)(H,104,127)(H,105,130)(H,106,134)(H,107,126)(H,108,131)(H,109,133)(H,110,135)(H,111,132)(H,112,128)(H,113,129)(H,119,120)(H,121,122)(H,136,137)(H4,92,93,96)(H4,94,95,97)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1

SMILES Code: CC(C)C[C@@H](C(O)=O)NC(CNC(CNC([C@H](CCC(O)=O)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,942.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Nelson M, Nelson DS, Cianciolo GJ, Snyderman R. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother. 1989;30(2):113-8. doi: 10.1007/BF01665962. PMID: 2598177.

2: Huang SS, Huang JS. A pentacosapeptide (CKS-25) homologous to retroviral envelope proteins possesses a transforming growth factor-beta activity. J Biol Chem. 1998 Feb 27;273(9):4815-8. doi: 10.1074/jbc.273.9.4815. PMID: 9478918.

3: Nelson M, Nelson D. Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide. Cancer Immunol Immunother. 1990;30(6):331-41. doi: 10.1007/BF01786882. PMID: 2302724.

4: Blinov VM, Krasnov GS, Shargunov AV, Shurdov MA, Zverev VV. [Mechanisms of retroviral immunosuppressive domain-induced immune modulation]. Mol Biol (Mosk). 2013 Sep-Oct;47(5):707-16. Russian. PMID: 25509343.

5: Takahashi A, Day NK, Luangwedchakarn V, Good RA, Haraguchi S. A retroviral- derived immunosuppressive peptide activates mitogen-activated protein kinases. J Immunol. 2001 Jun 1;166(11):6771-5. doi: 10.4049/jimmunol.166.11.6771. PMID: 11359835.

6: Fan Tx, Day NK, Luangwedchakarn V, Chang Y, Ikehara S, Lerner DL, Haraguchi S. The phosphorylation of phospholipase C-gamma1, Raf-1, MEK, and ERK1/2 induced by a conserved retroviral peptide. Peptides. 2005 Nov;26(11):2165-74. doi: 10.1016/j.peptides.2005.04.009. Epub 2005 Jun 22. PMID: 15978701.

7: Haraguchi S, Liu WT, Cianciolo GJ, Good RA, Day NK. Suppression of human interferon-gamma production by a 17 amino acid peptide homologous to the transmembrane envelope protein of retroviruses: evidence for a primary role played by monocytes. Cell Immunol. 1992 May;141(2):388-97. doi: 10.1016/0008-8749(92)90157-k. PMID: 1576656.

8: Luangwedchakarn V, Day NK, Hitchcock R, Brown PG, Lerner DL, Rucker RP, Cianciolo GJ, Good RA, Haraguchi S. A retroviral-derived peptide phosphorylates protein kinase D/protein kinase Cmu involving phospholipase C and protein kinase C. Peptides. 2003 May;24(5):631-7. doi: 10.1016/s0196-9781(03)00137-2. PMID: 12895647.

9: Haraguchi S, Good RA, Day-Good NK. A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways. Immunol Res. 2008;41(1):46-55. doi: 10.1007/s12026-007-0039-6. PMID: 18506644.

10: Iyonaga K, Miyajima M, Suga M, Saita N, Ando M. Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol. 1997 Jun;182(2):217-24. doi: 10.1002/(SICI)1096-9896(199706)182:2<217::AID-PATH833>3.0.CO;2-A. PMID: 9274534.

Your view history

Cks 17 featured